No Exposure to Silicon Valley Bank

RNS Number : 7227S
Instem plc
13 March 2023
 

Instem plc

  ("Instem", the "Group" or the "Company")

 

No Exposure to Silicon Valley Bank

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, notes media reports indicating the closure of Silicon Valley Bank ("SVB"). The Company does not hold any cash at SVB and it does not have a banking relationship with or any exposure to SVB.

 

For further information, please contact:

 

Instem plc

Via Walbrook

Phil Reason, CEO


Nigel Goldsmith, CFO




Singer Capital Markets (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Peter Steel
Alex Bond

Oliver Platts




Stifel Nicolaus Europe Limited (Joint Broker)

+44 (0) 20 7710 7600

Ben Maddison

 

Alex Price

Richard Short

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Tom Cooper

instem@walbrookpr.com

Nick Rome

Joe Walker




 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

 

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

 

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFFDVRIVLIV

Companies

Instem (INS)
UK 100